Sanofi puts new CSO in Boston, adding more weight to U.S. R&D

Sanofi's ($SNY) center of gravity is continuing its shift toward the U.S. The French drugmaker not only recruited a top official at the National Institutes of Health to be its chief scientific officer. It also decided to place him in the Boston area, where it set up an R&D hub last year. Report

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.